Outcomes with revascularisation versus conservative management of participants with 3-vessel coronary artery disease in the ISCHEMIA trial.

Autor: Bangalore S; Department of Medicine, New York University Grossman School of Medicine, New York, NY, USA., Rhodes G; Duke Clinical Research Institute, Durham, NC, USA., Maron DJ; Department of Medicine, Stanford University, Stanford, CA, USA., Anthopolos R; Department of Medicine, New York University Grossman School of Medicine, New York, NY, USA., O'Brien SM; Duke Clinical Research Institute, Durham, NC, USA., Jones PG; Saint Luke's Mid America Heart Institute, University of Missouri-Kansas City, Kansas City, MO, USA., Mark DB; Duke Clinical Research Institute, Durham, NC, USA., Reynolds HR; Department of Medicine, New York University Grossman School of Medicine, New York, NY, USA., Spertus JA; Saint Luke's Mid America Heart Institute, University of Missouri-Kansas City, Kansas City, MO, USA., Stone GW; The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA., White HD; Te Whatu Ora Health New Zealand, Te Toka Tumai, Green Lane Cardiovascular Services and University of Auckland, Auckland, New Zealand., Xu Y; Department of Medicine, New York University Grossman School of Medicine, New York, NY, USA., Fremes SE; University of Toronto, Sunnybrook Health Sciences Centre, Toronto, ON, Canada., Hochman JS; Department of Medicine, New York University Grossman School of Medicine, New York, NY, USA., Ischemia Research Group OBOT

Publikováno v: EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology [EuroIntervention] 2024 Oct 21; Vol. 20 (20), pp. e1276-e1287. Date of Electronic Publication: 2024 Oct 21.